Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.

Journal: Journal of translational medicine
Published Date: Aug 18, 2025

Abstract

BACKGROUND: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, some patients do not respond well, and some experience rapid progression despite initial benefit. This study aims to develop multimodal models integrating pre-treatment histopathological images and clinical variables to predict EGFR-TKIs therapy response and progression-free survival (PFS) in stage IV NSCLC patients.

Authors

  • Xiaodong Chai
    School of Urban Railway Transportation, Shanghai University of Engineering Science, Shanghai 201620, China.
  • Hongxia Li
    Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, People's Republic of China.
  • Moxuan Yang
    Department of Physics, Capital Normal University, Beijing, China.
  • Junyang Zeng
    College of Light Industry Science and Engineering, Tianjin University of Science and Technology, Tianjin, China.
  • Genxiu Chen
    China University of Petroleum-Beijing at Karamay, Karamay, China.
  • Yongmeng Li
    Department of Thoracic Surgery, Qianfoshan Hospital in the Shandong Province, Jinan, Shandong, China.
  • Wei Wang
    State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China.
  • Zichen Liu
    Department of Pathology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
  • Kun Li
    State Key Laboratory of Veterinary Etiological Biology National Foot-and-Mouth Disease Reference Laboratory Lanzhou Veterinary Research Institute Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China.
  • Tongmei Zhang
    Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
  • Shuhao Wang
    Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, 100084, P. R. China.
  • Nanying Che
    Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China cheny0448@163.com.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals